Zentalis Pharmaceuticals (ZNTL) Competitors $3.13 +0.03 (+0.97%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ZNTL vs. NUVB, AVBP, IMTX, REPL, QURE, ETNB, PLRX, RLAY, AVXL, and IMNMShould you be buying Zentalis Pharmaceuticals stock or one of its competitors? The main competitors of Zentalis Pharmaceuticals include Nuvation Bio (NUVB), ArriVent BioPharma (AVBP), Immatics (IMTX), Replimune Group (REPL), uniQure (QURE), 89bio (ETNB), Pliant Therapeutics (PLRX), Relay Therapeutics (RLAY), Anavex Life Sciences (AVXL), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Zentalis Pharmaceuticals vs. Nuvation Bio ArriVent BioPharma Immatics Replimune Group uniQure 89bio Pliant Therapeutics Relay Therapeutics Anavex Life Sciences Immunome Nuvation Bio (NYSE:NUVB) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk. Is NUVB or ZNTL more profitable? Nuvation Bio's return on equity of -21.89% beat Zentalis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation BioN/A -21.89% -17.86% Zentalis Pharmaceuticals N/A -43.91%-34.96% Do analysts prefer NUVB or ZNTL? Nuvation Bio currently has a consensus target price of $6.60, indicating a potential upside of 134.46%. Zentalis Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 219.49%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Zentalis Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has preferable earnings and valuation, NUVB or ZNTL? Nuvation Bio is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation BioN/AN/A-$75.80M-$2.17-1.30Zentalis PharmaceuticalsN/AN/A-$292.19M-$2.49-1.26 Do insiders and institutionals have more ownership in NUVB or ZNTL? 61.7% of Nuvation Bio shares are held by institutional investors. 5.1% of Nuvation Bio shares are held by company insiders. Comparatively, 3.6% of Zentalis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer NUVB or ZNTL? Zentalis Pharmaceuticals received 16 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 78.18% of users gave Nuvation Bio an outperform vote while only 63.44% of users gave Zentalis Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNuvation BioOutperform Votes4378.18% Underperform Votes1221.82% Zentalis PharmaceuticalsOutperform Votes5963.44% Underperform Votes3436.56% Which has more volatility and risk, NUVB or ZNTL? Nuvation Bio has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Zentalis Pharmaceuticals has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Does the media refer more to NUVB or ZNTL? In the previous week, Zentalis Pharmaceuticals had 1 more articles in the media than Nuvation Bio. MarketBeat recorded 3 mentions for Zentalis Pharmaceuticals and 2 mentions for Nuvation Bio. Zentalis Pharmaceuticals' average media sentiment score of 0.89 beat Nuvation Bio's score of 0.83 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryNuvation Bio beats Zentalis Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZNTL vs. The Competition Export to ExcelMetricZentalis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$220.92M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-1.2610.75135.1817.54Price / Sales5.50287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book0.515.394.884.92Net Income-$292.19M$152.04M$118.97M$225.78M7 Day Performance-10.57%-4.32%15.73%-1.58%1 Month Performance2.62%2.80%15.69%6.67%1 Year Performance-77.45%17.30%34.73%22.48% Zentalis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZNTLZentalis Pharmaceuticals2.544 of 5 stars$3.13+1.0%$10.00+219.5%-78.7%$220.92M$40.56M-1.26160NUVBNuvation Bio1.9641 of 5 stars$2.71+3.8%$6.60+143.5%+99.6%$912.11MN/A0.0060AVBPArriVent BioPharma1.1598 of 5 stars$26.75+0.1%$36.80+37.6%N/A$901.40MN/A0.0040Short Interest ↑Positive NewsIMTXImmatics1.5356 of 5 stars$7.33+1.7%$16.67+127.4%-26.8%$874.88M$115.50M-10.92260Short Interest ↑REPLReplimune Group4.6085 of 5 stars$12.69+1.1%$17.29+36.2%+45.4%$868.25MN/A-4.11210Positive NewsQUREuniQure3.6287 of 5 stars$17.31+12.4%$32.13+85.6%+99.0%$843.74M$28.59M-3.36500Analyst ForecastNews CoverageETNB89bio1.9127 of 5 stars$7.87+2.3%$30.33+285.4%-24.7%$835.21MN/A-2.6440Short Interest ↑Positive NewsPLRXPliant Therapeutics3.3301 of 5 stars$13.66+2.7%$40.50+196.5%-14.3%$831.21M$1.58M0.0090RLAYRelay Therapeutics2.3509 of 5 stars$4.89+3.8%$20.50+319.2%-55.6%$818.49M$25.55M-1.80304AVXLAnavex Life Sciences3.592 of 5 stars$9.26+9.5%$43.00+364.4%+4.2%$785.25MN/A-18.3640IMNMImmunome2.807 of 5 stars$12.44-1.1%$28.83+131.8%+59.4%$776.47M$10.13M-1.5540Short Interest ↓Positive News Related Companies and Tools Related Companies NUVB Competitors AVBP Competitors IMTX Competitors REPL Competitors QURE Competitors ETNB Competitors PLRX Competitors RLAY Competitors AVXL Competitors IMNM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZNTL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZNTL Stock Alerts